FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Which merger's better, Merck's or Pfizer's?

Tools

It's striking--bordering on shocking--how investors have reacted differently to the megamergers by Pfizer and Merck, Motley Fool says. Merck traded down right after the announcement, but investors have bid up the stock by 17 percent since Merck announced it would by Schering; conversely, Pfizer's shares are down 18.3 percent. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:

More stories about Pfizer   Wyeth   Merck   Schering-Plough   Mergers and Acquisitions   Pharma investing